-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, Hengrui Pharmaceuticals issued an announcement stating that the company had recently received the approval of the National Medical Products Administration for the "Drug Clinical Trial Approval Notice" for HRS 2300 tablets, and clinical trials will be launched in the near future
HRS2300 can inhibit the proliferation of tumor cells and exert anti-tumor effects.
Up to now, the accumulated R&D expenses of HRS2300 related R&D projects are about 18.